Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. This evidence concerns the gene MAP3K5 and metabolic dysfunction-associated steatohepatitis.